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EXPERIMENTAL STUDY
Persistent Primary Coronary Dilation
Induced by Transatrial Delivery
of Nitroglycerin Into the Pericardial Space:
A Novel Approach for Local Cardiac Drug Delivery
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Richard L. Verrier, PHD, FACC*†
Boston, Massachusetts
OBJECTIVES We compared the effects of intrapericardial and intracoronary nitroglycerin on coronary
cross-sectional area as assessed by intravascular ultrasound and demonstrated the feasibility of
local cardiac drug delivery by a newly developed method to access the normal pericardial space
through the right atrial appendage.
BACKGROUND Studies of nitric oxide (NO) donors have suggested that their antiarrhythmic and antipro-
liferative properties are more effective when administered by the intrapericardial rather than
intravascular route. We postulated that NO donors delivered intrapericardially would also
cause sustained coronary vasodilation without significant systemic hypotension.
METHODS Intrapericardial nitroglycerin (200 mg) was administered in five Yorkshire pigs. Coronary
cross-sectional luminal area was measured with intravascular ultrasound at various time
intervals. The effects of intracoronary nitroglycerin on coronary luminal area were used for
comparison.
RESULTS Transatrial pericardial access required 1 to 3 min in all animals. Intrapericardial nitroglycerin
was associated with a mean 31.7% increase in luminal area at 5 min (p , 0.001). Vasodilation
peaked between 5 and 10 min and persisted for 15 min. In contrast, intracoronary
nitroglycerin was associated with a smaller mean increase in luminal area (20.3% at 5 min, p ,
0.01) that disappeared by 10 min. Significant systemic hypotension was observed at 3 min
with intracoronary but not with intrapericardial nitroglycerin.
CONCLUSIONS Sustained coronary vasodilation can be achieved with intrapericardial delivery of nitroglycerin
without systemic hypotension. Nitric oxide donors with longer half-lives could prove
beneficial in the treatment of myocardial ischemic syndromes when administered through this
route. Transatrial pericardial access offers a novel route for local cardiac drug delivery. (J Am
Coll Cardiol 1999;33:2073–7) © 1999 by the American College of Cardiology
Studies of nitric oxide (NO) donors administered into the
pericardial space have demonstrated that this group of
vasodilators can decrease cyclic flow variations in
endothelium-injured coronaries (1) and decrease the prolif-
erative coronary vascular response after balloon injury (2) in
animals. It has been postulated that these agents are more
effective and are hemodynamically safer when administered
via this route (1), because the pericardium acts as a natural
barrier that minimizes systemic absorption and side effects
and provides a low rate turnover reservoir in which delivery
of a pharmacologic agent can achieve high concentrations
around the epicardium and epicardial vessels (3). Despite
these data supporting NO penetration to the coronary
media from the adventitial surface, there is no information
on whether NO donors or any other vasodilator delivered in
the pericardial space has an effect on epicardial coronary
reactivity.
We postulated that NO donors delivered intrapericardi-
ally would exert coronary vasodilation comparable to that
observed after intracoronary injection but would have the
added advantage of avoiding significant systemic hypoten-
sion. To test this hypothesis, we used a newly developed
nonsurgical technique for intrapericardial drug delivery
through the right atrial appendage. The effects of intraperi-
cardial and intracoronary administration of nitroglycerin, a
prototype NO donor, on coronary cross-sectional area as
assessed by intravascular ultrasound were compared.
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METHODS
The study was conducted according to National Institutes of
Health standards and conformed to the “Position of the
American Heart Association on Research Animal Use.” Pro-
tocols were approved by the Harvard Medical Area Standing
Committee on Animal Use. The studies were conducted in
seven Yorkshire pigs of either gender weighing 25 to 35 kg.
The animals were preanesthetized with intravenous ketamine
(15 mg/kg), xylazine (2.2 mg/kg) and atropine (0.04 mg/kg),
and anesthetized with alpha-chloralose (100 mg/kg IV). Tra-
cheostomy and endotracheal intubation were performed in all
animals. Arterial PO2, PCO2 and pH were maintained at
physiologic range with a volume ventilator and supplemental
oxygen as required. Heart rate was monitored from a surface
electrocardiogram. Both left and right femoral artery and vein
were cannulated with 8-F introducer sheaths using standard
percutaneous technique. Blood pressure was continuously
monitored through one of the femoral arterial sheaths.
Transatrial technique for accessing the pericardial space.
The technique for transatrial access into the pericardial
space was performed as previously described (4,5). An 8-F
multipurpose guide was positioned under fluoroscopic guid-
ance in the right atrial appendage (Fig. 1A). A custom-
fabricated 4-F catheter with a 21-ga needle mounted at the
tip was advanced through the guide, and a small perforation
was made in the right atrial appendage (Fig. 1B). A soft
0.014-in. (0.036 cm) guide wire was advanced through the
needle catheter and into the normal pericardial space (Fig.
1C). The guide wire confirms position in the pericardial
space by conforming to the contour of the heart, secures the
point of entry and allows over-the-wire exchanges of other
catheters. The needle catheter was withdrawn over the wire
and exchanged for a 4-F catheter with multiple side holes at
its distal end, which was positioned and left in the pericar-
dial space (Fig. 1D) for delivery of drugs. Radiopaque
markers at the tip of all catheters improved visualization
during fluoroscopy.
Catheterization and imaging system protocol. An 8-F
guiding catheter was inserted through either left or right
femoral arterial sheath and, under fluoroscopic guidance,
advanced into the ascending aorta and was engaged in the
ostium of the left main coronary artery. Heparin was
administered intravenously at a dose of 1,000 U. A 3.5-F
30-MHz intravascular ultrasound catheter (SoniCath,
Mansfield Corp., Watertown, Massachusetts) was advanced
into the proximal to mid-left anterior descending artery and
left in place for the rest of each experiment. Transducer
position was confirmed frequently by fluoroscopy, using the
distance between the tip of the guide and the imaging
catheter by fluoroscopy and the presence of side branches by
ultrasound as reference points. Ultrasound images were
displayed on a video monitor and recorded at 30 frames per
second on high resolution super VHS videotape. The
ultrasound was gated to the cardiac cycle, and for each
measurement, a single frame depicting the lumen at the
peak of the QRS wave, which corresponds to end diastole,
was selected. Lumen cross-sectional area at the intimal echo
boundary was traced with a trackball and cross-sectional
area was calculated by computerized planimetry. Reproduc-
ibility of lumen area measurements was determined by
blinded intraobserver repeated measures (r 5 0.97).
Nitroglycerin protocol. Arterial blood pressure, heart rate
and intracoronary dimensions by intravascular ultrasound
were recorded at baseline. Nitroglycerin (200 mg), admin-
istered as 0.5 ml of a 400-mg/cc solution followed by a 5-ml
saline bolus, was injected into the left coronary artery
through the guiding catheter in four pigs. This dose is
commonly used in humans during coronary angioplasty
procedures. Measurements were performed at 3, 5, 10, 15,
20, 25 and 30 min after injection. For intrapericardial
injection of nitroglycerin, 200 mg was diluted in 5 ml of
saline solution and injected through the 4-F intrapericardial
catheter in five animals. Arterial pressure, heart rate and
Abbreviations and Acronyms
bFGF 5 basic fibroblast growth factor
NO 5 nitric oxide
Figure 1. Fluoroscopic images demonstrating the method for
transatrial pericardial access. (A) The 8-F guide catheter (arrows)
rests against the wall of the right atrial appendage. (B) The needle
catheter (arrow) is protruding through the wall of the right atrial
appendage into the pericardial space. (C) The guide wire (arrows)
has been advanced through the needle catheter into the pericardial
space. (D) The 4-F delivery catheter (arrows) has been advanced
over the wire through the appendage wall and positioned in the
pericardial space.
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intracoronary dimensions were also measured at baseline
and at each of the time points mentioned above. Three of
the animals received both intracoronary and intrapericardial
nitroglycerin with $20-min waiting periods between each
experiment.
Statistical analysis. Data for each group (intrapericardial
or intracoronary) at the various time intervals were com-
pared with baseline using repeated measures analysis of
variance with Bonferroni post hoc test. Data were also
analyzed as percent change from baseline. The mean values
in each group were compared with each other to look for a
difference in the overall response curve between groups
using a two-way repeated measures analysis of variance.
Coronary luminal area change in response to intracoronary
versus intrapericardial nitroglycerin administration was also
estimated as the area under the curve and calculated using
the numerical integration method of the trapezoidal rule
equation (6). This technique involves constructing adjoining
trapezoidal panels and calculating and summing the areas of
all trapezoids that are fit under the empirical curve of the
luminal diameter versus time plot.
RESULTS
After percutaneous placement of the arterial and venous
femoral sheaths, access into the normal pericardial space
required 1 to 3 min. No hemodynamic or electrocardio-
graphic changes resulted from transatrial pericardial access.
Effects of nitroglycerin on coronary vasodilation. Intra-
coronary nitroglycerin was associated with a mean 20.3%
increase in luminal area at 5 min as compared with baseline
(p , 0.01). The vasodilatory effect peaked at 3 to 5 min
after injection (from 9.27 mm2 6 0.68 SEM at baseline to
10.83 mm2 6 0.54 SEM at 3 min, p , 0.05, and to
11.15 mm2 6 0.45 SEM at 5 min, p , 0.01) and
disappeared by 10 min. In contrast, intrapericardial nitro-
glycerin was associated with a mean 31.7% increase in
luminal area at 5 min as compared with baseline (p ,
0.001). This greater increase in luminal area was also
significantly more sustained than that observed with intra-
coronary administration, because it peaked between 5 and
10 min and persisted for more than 15 min (from
9.9 mm2 6 0.84 SEM at baseline to 12.84 mm2 6 1.48
SEM at 3 min to 13.04 mm2 6 1.42 SEM at 5 min, to
12.92 mm2 6 1.26 SEM at 10 min and to 12.52 mm2 6
1.30 SEM at 15 min, all comparisons with baseline, p ,
0.001). Intrapericardial nitroglycerin produced a greater
absolute luminal area dilation (p 5 0.03) and percent area
change (p , 0.005) than intracoronary administration (Fig.
2). The magnitude of the vasodilatory effect by trapezoidal
analysis was 363.2 mm2 3 min for intrapericardial com-
pared with 285.6 mm2 3 min for intracoronary nitroglyc-
erin administration.
Effects of nitroglycerin on hemodynamic parameters.
With intracoronary nitroglycerin, there was a significant
and transitory increase in mean heart rate (86.2 bpm 6 4.7
SEM to 97.2 bpm 6 2.7 SEM, p , 0.001) and a decrease
in mean arterial pressure (94.7 mm Hg 6 2.7 SEM to
83.5 mm Hg 6 5.5 SEM, p , 0.01) at 3 min as compared
with baseline. The hypotensive effect of intracoronary ni-
troglycerin was transitory and occurred in the first 3 min
after injection, with subsequent return of the arterial pres-
sure to baseline. In contrast, mean arterial pressure and
heart rate did not change at any point after intrapericardial
administration.
DISCUSSION
We demonstrated that nitroglycerin administered directly
into the pericardial space has a coronary vasodilator effect
which is more sustained and of greater magnitude than that
observed with intracoronary injection. This effect is not
associated with the hypotensive response that is usually seen
with intravascular delivery. Our finding that coronary vaso-
dilation, and therefore smooth muscle cell relaxation, can be
induced by intrapericardial nitroglycerin administration
supports this approach to targeting the coronary media and
intima.
Previous studies with NO donors. Nitric oxide donors
have been utilized intravenously to minimize the response to
ischemia/reperfusion injury, inhibit ischemic arrhythmias
and limit infarct size (7–11). More recently, intrapericardial
use of these compounds has been proposed as a route for
optimizing their effects while minimizing side effects. Baek
and associates (2) demonstrated that intrapericardial NO
donors decrease the neointimal proliferative response after
balloon coronary injury in pigs, suggesting penetration into
smooth muscle and endothelial cells from the adventitial
surface. Fei and colleagues (7) reported that intrapericardial
delivery of L-arginine, the precursor of NO, reduced the
Figure 2. Bar graph comparing the effects of intrapericardial
(diamonds) and intracoronary (squares) nitroglycerin on left
anterior descending coronary artery luminal area as assessed by
intravascular ultrasound. The asterisks indicate significance with
respect to baseline value (***p , 0.001, **p , 0.01, *p , 0.05). The
curves were statistically different using two-way analysis of variance
(p 5 0.03). Values are presented as means 6 standard errors.
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severity of ventricular arrhythmias during sympathetic stim-
ulation in a canine model of acute coronary occlusion. In
their study, NO overflow (NO concentration 3 blood flow)
in the coronary sinus increased after intrapericardial
L-arginine, suggesting increased activity of smooth muscle
or endothelial cell NO-synthase even though the amino acid
was administered on the epicardial surface. Moreover,
Willerson and colleagues (1) reported that intrapericardial
nitroprusside, an NO donor, decreases platelet aggregation
in the coronary circulation and cyclic flow variation in
endothelium-injured coronary arteries. These effects were
more pronounced and the required doses were smaller with
intrapericardial than with intravenous administration. They
also demonstrated a smaller dose-dependent reduction in
aortic pressure with intrapericardial than with intravenous
nitroprusside. Similarly, in our study, the decrease in arterial
pressure was much less pronounced with intrapericardial
than with intracoronary nitroglycerin, suggesting that ab-
sorption into the peripheral circulation may be minimized
by the barrier action of the pericardium.
Studies of other intrapericardially delivered agents. The
sustained coronary vasodilator effect of intrapericardial de-
livery of nitroglycerin suggests that the drug is contained
within the pericardial space, prolonging the time of action
and exposure to perivascular tissue, and is not diffused
rapidly into the systemic circulation. In contrast, intracoro-
nary or intravenous administration of nitroglycerin is lim-
ited by a relatively short duration of action, with minimal or
no organ selectivity, and is associated with systemic effects
such as hypotension. These limitations may be particularly
important when considering administration of vascular or
myocardial growth factors, viral vectors or other proteins to
induce angiogenesis or improve contractility, whose possible
side effects include intimal hyperplasia, mitogenesis and
systemic toxicity (12–15). For such agents, exposure to
myocardial tissue needs to be maximized while minimizing
availability to other organs. Lazarous and coworkers (16)
demonstrated that intrapericardial administration of basic
fibroblast growth factor (bFGF) via thoracotomy resulted in
the highest myocardial uptake of bFGF as compared with
intravascular delivery. Moreover, the lower systemic absorp-
tion from the pericardial space is further supported by their
findings that after intrapericardial administration, a signif-
icantly smaller percentage of bFGF could be recovered in
extra cardiac tissues (16). Further interest has been gener-
ated in attaining cardioselective pharmacologic action with
intrapericardial delivery of diverse agents such as prostaglan-
dins (17), autonomic blockers (18,19), bradykinin (20) and
antiarrhythmic agents (21–23).
Until recently, the delivery of pharmacologic agents into
the normal pericardial space has been limited by the
inability to access this space without thoracotomy. Surgical
pericardial window and needle pericardiocentesis are usually
performed only in the setting of significant pericardial
effusion. Our study demonstrates the feasibility of the
percutaneous approach for transatrial access to the normal
pericardial space. The method provides rapid access and is
performed through femoral venous access such as in routine
right heart catheterization. It has been previously employed
for pericardiocentesis in animal models (4). Further studies
will be required to test its feasibility and safety for human
use.
Study limitations. It remains to be determined whether
the epicardial vasodilatory effect of localized delivery of
nitroglycerin can be exploited clinically. Its utility in the
clinical setting of coronary obstruction or diffuse atheroscle-
rotic disease is not established. Because flow was not
measured, we cannot determine whether the observed
changes in epicardial diameter are associated with increased
flow. Given the lack of change in arterial blood pressure
with concomitant increase in coronary diameter, a flow
increase is postulated.
Clinical implications. We demonstrated that sustained
and significant coronary vasodilation can be achieved by
intrapericardial delivery of nitroglycerin, circumventing the
hypotensive effect of this agent when administered by
conventional routes. Intrapericardial delivery of NO donors
or other vasodilators could prove beneficial in the treatment
of refractory ischemic syndromes or severe, diffuse coronary
artery disease. The ability to access the normal pericardial
space with the transatrial method also offers a novel route
for local delivery of antiarrhythmics, angiogenic factors,
myocardial protection (24) and other agents designed to
improve myocardial contractility or modulate the vessel wall
response in atherosclerosis.
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